利伐沙班长期吃有什么影响

(Rivaroxaban) can highly selectively and competitively bind to the active site of factor Xa. This reversible binding can interrupt the intrinsic and extrinsic pathways of the coagulation cascade, inhibiting thrombin generation and thrombosis. Although patients can benefit a lot by insisting on taking this drug, they may still experience some adverse reactions during long-term use, and patients need to pay high attention to this.

In a domestic study, there were no deaths during treatment with rivaroxaban and warfarin. One case of asymptomatic venous thrombosis occurred in the rivaroxaban group at 6 months and 12 months, with an incidence rate of 4.55%. There were 2 and 3 cases of asymptomatic venous thrombosis in the warfarin group at 3 months and 6 months respectively. Two cases of pulmonary embolism occurred at 6 months, with an incidence of thrombotic events of 15.22%; 3 cases in the rivaroxaban group One case of hemoptysis occurred at 6 months, and 2 cases of positive fecal occult blood occurred at 6 months, with an incidence rate of 6.82%. There were 2 cases of positive fecal occult blood in the warfarin group at 3 months and 6 months, with an incidence rate of 8.70%. There was no significant difference in the effectiveness and safety of preventing thrombotic diseases between the two groups.

Although the antithrombotic effect of warfarin is clear and reliable, there are still many problems with the drug itself and its use. Since its launch, rivaroxaban (i.e. Xarelto) has been mainly used to prevent venous thrombosis, acute coronary syndrome and non-valvular atrial fibrillation in adult hip and knee replacement surgeries. During use, special attention should be paid to patients with liver and kidney damage, which may significantly increase the plasma concentration of rivaroxaban, and more caution should be used when using it. As a new anticoagulant drug, bleeding is still its most important complication. Therefore, Xarelto is contraindicated in patients with liver disease who have obvious active bleeding or coagulation abnormalities and are at risk of bleeding.

Recommended hot articles: /newsDetail/73279.html